PT  - JOURNAL ARTICLE
AU  - DEBORA M.I. FERSCHING
AU  - DOROTHEA NAGEL
AU  - BARBARA SIEGELE
AU  - CHRISTOPH SALAT
AU  - VOLKER HEINEMANN
AU  - STEFAN HOLDENRIEDER
AU  - OLIVER J. STOETZER
TI  - Apoptosis-related Biomarkers sFAS, MIF, ICAM-1 and PAI-1 in Serum of Breast Cancer Patients Undergoing Neoadjuvant Chemotherapy
DP  - 2012 May 01
TA  - Anticancer Research
PG  - 2047--2058
VI  - 32
IP  - 5
4099  - http://ar.iiarjournals.org/content/32/5/2047.short
4100  - http://ar.iiarjournals.org/content/32/5/2047.full
SO  - Anticancer Res2012 May 01; 32
AB  - Background: Neoadjuvant chemotherapy improves surgical options and prognosis in patients with operable breast cancer. Predictive biomarkers are needed to choose the most effective therapy and to avoid unnecessary toxicity. Patients and Methods: We analyzed the courses of apoptosis-related serum biomarkers macrophage migration-inhibitory factor (MIF), soluble cell death receptor sFAS, soluble intercellular adhesion molecule (sICAM), plasminogen activator inhibitor 1 (PAI-1) as well as the oncological biomarkers carcino-embryonic antigen (CEA) and carbohydrate antigen 15-3 (CA15-3) in prospectively collected sera of 51 patients with locally confined breast cancer undergoing preoperative chemotherapy. As controls 31 healthy women, 13 patients with benign breast disease and 28 patients with metastasized breast cancer were included. Results: sFAS, MIF, CEA and CA15-3 showed significantly higher serum concentrations in patients with metastasized breast cancer than in healthy and benign controls. Additionally, sFAS and MIF discriminated between locally confined breast cancer and healthy controls with an area under the curve (AUC) in receiver operating characteristic (ROC) curves of 73.4% and 70.7%. After neoadjuvant chemotherapy, 38 patients achieved complete (N=9) or partial (N=29) remission, while 13 patients had no change of disease. Pretherapeutic levels of MIF were considerably higher in non-responsive patients (p=0.082). In addition, post-therapeutic sICAM and CA15-3 levels were higher in patients without complete remission. Conclusion: Apoptosis-related biomarkers are valuable markers in breast cancer patients and show potential for early estimation of the efficiency of neoadjuvant chemotherapy.